Related Experiment Video
Updated: May 9, 2026

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel
Published on: June 29, 2015
Tpl2 kinase regulates FcγR signaling and immune thrombocytopenia in mice
Irene Kyrmizi1, Marianna Ioannou, Maria Hatziapostolou
12.Div. of Allergy, Clinical Immunology and Rheumatology, New York Medical College, 40 Sunshine Cottage Rd., Valhalla, NY 10595, USA. Ioannis_Tassiulas@nymc.edu.
Abstract:
The MAPK3 Tpl2 controls innate and adaptive immunity by regulating TLR, TNF-α, and GPCR signaling in a variety of cell types. Its ablation gives rise to an anti-inflammatory phenotype characterized by resistance to LPS-induced endotoxin shock, DSS-induced colitis, and TNF-α-induced IBD. Here, we address the role of Tpl2 in autoimmunity. Our data show that the ablation and the pharmacological inhibition of Tpl2 protect mice from antiplatelet antibody-induced thrombocytopenia, a model of ITP. Thrombocytopenia in this model and in ITP is caused by phagocytosis of platelets opsonized with antiplatelet antibodies and depends on FcγR activation in splenic and hepatic myeloid cells. Further studies explained how Tpl2 inhibition protects from antibody-induced thrombocytopenia, by showing that Tpl2 is activated by FcγR signals in macrophages and that its activation by these signals is required for ERK activation, cytoplasmic Ca(2+) influx, the induction of cytokine and coreceptor gene expression, and phagocytosis.
Insights
The Tpl2 protein regulates immune responses. Inhibiting Tpl2 protects mice from autoimmune conditions like immune thrombocytopenia (ITP) by blocking harmful platelet destruction.
Area of Science:
- Immunology
- Molecular Biology
- Autoimmunity
Background:
- The MAPK3 Tpl2 kinase is a key regulator of innate and adaptive immunity, influencing Toll-like receptor (TLR), tumor necrosis factor-alpha (TNF-α), and G-protein coupled receptor (GPCR) signaling.
- Tpl2 deficiency results in an anti-inflammatory phenotype, conferring resistance to endotoxin shock, colitis, and inflammatory bowel disease (IBD).
Purpose of the Study:
- To investigate the role of Tpl2 in the development of autoimmune diseases.
- To determine if Tpl2 inhibition can protect against immune thrombocytopenia (ITP).
Main Methods:
- Utilized mouse models with Tpl2 ablation (genetic knockout) and pharmacological inhibition.
- Induced antiplatelet antibody-mediated thrombocytopenia, a model for ITP.
- Analyzed FcγR signaling pathways in splenic and hepatic myeloid cells, focusing on Tpl2 activation, ERK signaling, calcium influx, and gene expression.
Main Results:
- Ablation and pharmacological inhibition of Tpl2 significantly protected mice from developing antiplatelet antibody-induced thrombocytopenia.
- Thrombocytopenia in this model is driven by FcγR-mediated phagocytosis of antibody-opsonized platelets by myeloid cells.
- Tpl2 is activated by FcγR signaling in macrophages, and this activation is crucial for downstream ERK activation, calcium influx, cytokine/coreceptor gene induction, and subsequent phagocytosis.
Conclusions:
- Tpl2 plays a critical role in FcγR-mediated phagocytosis and the pathogenesis of autoimmune thrombocytopenia.
- Pharmacological inhibition of Tpl2 represents a potential therapeutic strategy for treating ITP and potentially other FcγR-driven autoimmune disorders.
Related Concept Videos
Intracellular Signaling Affects Focal Adhesions
Some...
PI3K/mTOR/AKT Signaling Pathway
Receptor Tyrosine Kinases
Amplifying Signals via Enzymatic Cascade
The JAK-STAT Signaling Pathway

